LV12315B - RISPERIDON BASIC - Google Patents

RISPERIDON BASIC Download PDF

Info

Publication number
LV12315B
LV12315B LVP-99-32A LV990032A LV12315B LV 12315 B LV12315 B LV 12315B LV 990032 A LV990032 A LV 990032A LV 12315 B LV12315 B LV 12315B
Authority
LV
Latvia
Prior art keywords
risperidone
pamoate
composition
composition according
compound according
Prior art date
Application number
LVP-99-32A
Other languages
English (en)
Latvian (lv)
Other versions
LV12315A (lv
Inventor
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of LV12315A publication Critical patent/LV12315A/xx
Publication of LV12315B publication Critical patent/LV12315B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
LVP-99-32A 1993-04-28 1999-02-24 RISPERIDON BASIC LV12315B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93201216 1993-04-28

Publications (2)

Publication Number Publication Date
LV12315A LV12315A (lv) 1999-07-20
LV12315B true LV12315B (en) 2000-03-20

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-32A LV12315B (en) 1993-04-28 1999-02-24 RISPERIDON BASIC

Country Status (32)

Country Link
US (2) US5612346A (ru)
EP (1) EP0697019B1 (ru)
JP (1) JP3478397B2 (ru)
KR (1) KR100307101B1 (ru)
CN (1) CN1041727C (ru)
AT (1) ATE163418T1 (ru)
AU (1) AU675136B2 (ru)
BG (1) BG62004B1 (ru)
CA (1) CA2160366C (ru)
CY (1) CY2107B1 (ru)
CZ (1) CZ286688B6 (ru)
DE (1) DE69408666T2 (ru)
DK (1) DK0697019T3 (ru)
ES (1) ES2113652T3 (ru)
FI (1) FI109125B (ru)
GR (1) GR3026028T3 (ru)
HK (1) HK1006059A1 (ru)
HU (1) HU218212B (ru)
IL (1) IL109448A (ru)
LV (1) LV12315B (ru)
NO (1) NO305083B1 (ru)
NZ (1) NZ266143A (ru)
PH (1) PH30476A (ru)
PL (1) PL182466B1 (ru)
RO (1) RO115955B1 (ru)
RU (1) RU2131428C1 (ru)
SG (1) SG47046A1 (ru)
SI (1) SI9420031B (ru)
SK (1) SK280589B6 (ru)
TW (1) TW376319B (ru)
WO (1) WO1994025460A1 (ru)
ZA (1) ZA942909B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3645906B2 (ja) 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ マイクロカプセル封入された3−ピペリジニル−置換1,2−ベンズイソオキサゾール類及び1,2−ベンズイソチアゾール類
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CZ300725B6 (cs) * 1997-09-30 2009-07-29 Eli Lilly And Company 2-Methylthienbenzodiazepinová formulace
UA72189C2 (ru) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Водные суспензии субмикронной формы эфиров 9-гидроксирисперидона жирных кислот
UA66872C2 (ru) * 1998-09-30 2004-06-15 Елі Ліллі Енд Компані Композиции олазанпина, памоата олазанпина или его сольватов и способ лечения психотических расстройств
EP1129094A2 (en) * 1998-11-12 2001-09-05 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004017975A1 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
EP1615924A1 (en) * 2003-04-22 2006-01-18 Synthon B.V. Water soluble salts of risperidone
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
MXPA06004489A (es) * 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
ATE511512T1 (de) * 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
NZ582415A (en) * 2007-07-31 2012-05-25 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
KR102318070B1 (ko) * 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
PL3156056T3 (pl) 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
PL2702060T3 (pl) 2011-04-26 2016-06-30 Torrent Pharmaceuticals Ltd Kwasowe addycyjne sole risperidonu i ich kompozycje farmaceutyczne
JP6333802B2 (ja) * 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
NZ630703A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
CA2868381C (en) 2012-04-04 2020-07-07 Intervet International B.V. Soft chewable pharmaceutical products
CN102659577B (zh) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 一种亚甲基双羟基萘酸的制备方法
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
MX367782B (es) * 2012-09-26 2019-09-04 Tangent Reprofiling Ltd Moduladores de la sintesis de andrógenos.
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技(厦门)有限公司 可乐定双羟萘酸盐及其制备方法
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
SG47046A1 (en) 1998-03-20
TW376319B (en) 1999-12-11
DE69408666D1 (de) 1998-04-02
DE69408666T2 (de) 1998-06-18
BG100094A (bg) 1996-05-31
FI955166A (fi) 1995-10-27
KR100307101B1 (ko) 2001-11-30
LV12315A (lv) 1999-07-20
CA2160366A1 (en) 1994-11-10
JP3478397B2 (ja) 2003-12-15
PL311282A1 (en) 1996-02-05
PL182466B1 (pl) 2002-01-31
CN1041727C (zh) 1999-01-20
CZ286688B6 (en) 2000-06-14
FI955166A0 (fi) 1995-10-27
US5723467A (en) 1998-03-03
AU675136B2 (en) 1997-01-23
RU2131428C1 (ru) 1999-06-10
BG62004B1 (bg) 1998-12-30
AU6721694A (en) 1994-11-21
PH30476A (en) 1997-05-28
IL109448A (en) 1997-03-18
SK131395A3 (en) 1996-06-05
CA2160366C (en) 2006-06-06
HK1006059A1 (en) 1999-02-05
HUT72970A (en) 1996-06-28
US5612346A (en) 1997-03-18
ES2113652T3 (es) 1998-05-01
HU218212B (hu) 2000-06-28
ZA942909B (en) 1995-10-26
IL109448A0 (en) 1994-07-31
SI9420031A (en) 1996-08-31
EP0697019A1 (en) 1996-02-21
NO954275D0 (no) 1995-10-26
SK280589B6 (sk) 2000-04-10
NO954275L (no) 1995-10-26
DK0697019T3 (da) 1998-09-28
JPH08509482A (ja) 1996-10-08
SI9420031B (sl) 2002-08-31
NZ266143A (en) 1996-07-26
CZ270695A3 (en) 1996-01-17
CY2107B1 (en) 2002-04-26
ATE163418T1 (de) 1998-03-15
WO1994025460A1 (en) 1994-11-10
EP0697019B1 (en) 1998-02-25
FI109125B (fi) 2002-05-31
CN1121719A (zh) 1996-05-01
NO305083B1 (no) 1999-03-29
GR3026028T3 (en) 1998-04-30
RO115955B1 (ro) 2000-08-30
HU9501934D0 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
LV12315B (en) RISPERIDON BASIC
US4725691A (en) 2-[8-quinolinyl]-sulphinyl-1H-benzimidazole
PL188908B1 (pl) Nowe pochodne benzimidazolu i ich zastosowanie dowytwarzania leków do leczenia stanów alergicznych
US3399201A (en) Aminoalkyl-ethano-anthracenes
DE60112254T2 (de) Benzthiazolderivate die tnf und pde-iv hemmen
GB1561561A (en) Bis (i-phenoxyalkane carboxylic acids) and derivatives thereof process for their preparation and their use as medicaments
LV10868B (en) Oxadiazolyl-alkyl-purine derivatives
EP0089028B1 (de) Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung
JPH0568476B2 (ru)
US4052390A (en) Azapurinones
JPH0377885A (ja) 2―オキソ―1―オキサ―8―アザスピロ〔4,5〕デカン誘導体、それを含む医薬組成物及びその製造方法
JPS5874678A (ja) チアキサンテン誘導体のアルフア異性体のエステルと該エステルの酸附加塩とを製造し且つ精製する方法
US3177211A (en) 10-[(aminocarbamyl-1-piperidyl)-loweralkyl]-phenothiazines
GB2081708A (en) Novel derivatives of (1-benzyl-1h-indazol-3-yl) oxyacetic acid and pharmaceutical composition containing it
US3632653A (en) Ethano-anthracenes
US5883255A (en) Substituted indolizino 1,2-b!quinolinones
US3489799A (en) Ethano-anthracenes
JPS6222992B2 (ru)
CZ380596A3 (en) Salts of 2-(2,6-dichlorophenyl)amino)phenylacetoxyacetic acid with cations of organic bases, process of their preparation, pharmaceutical compositions containing thereof and their use
IE42161B1 (en) Pyrano-quinoline carboxylic acids,processes for their preparation and their use as pharmaceutical agents
AU614757B2 (en) Hydroquinonylphenyl butyric acid amide derivative
JP3029870B2 (ja) キノリン誘導体
JPH0368576A (ja) 薬学的に活性な2―置換された3―(2―エトキシエチル)イミダゾ〔4,5―b〕ピリジンおよび該化合物を含有する薬学的組成物
JPH09124608A (ja) シクロプロパン誘導体及びそれを含有する抗ウイルス剤